These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34407581)

  • 1. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
    Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
    [No Abstract]   [Full Text] [Related]  

  • 2. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 5. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Jackson S; Ryder S; Cramp M; Stein K
    Br J Cancer; 2008 Apr; 98(7):1166-75. PubMed ID: 18382459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
    Nan Y; Garay OU; Lu X; Zhang Y; Xie L; Niu Z; Chen W
    J Comp Eff Res; 2024 Apr; 13(4):e230146. PubMed ID: 38415341
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
    Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
    BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
    Xie L; Yin J; Xia R; Zhuang G
    Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
    Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
    World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
    Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic evaluation of hepatocellular carcinoma surveillance in chronic hepatitis B patients with virological remission.
    Fang K; Li S; Lin Y; Zhang Y; Wu J
    BMC Public Health; 2024 Aug; 24(1):2202. PubMed ID: 39138480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis.
    Kao SZ; Sangha K; Fujiwara N; Hoshida Y; Parikh ND; Singal AG
    EClinicalMedicine; 2024 Sep; 75():102755. PubMed ID: 39234558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.